RJA
EFTR

Raymond James & Associates’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Raymond James & Associates’s Portfolio EFTR Stock Details EFTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12,345
Closed -$178K – 4108
2024
Q1 		$178K Buy
+12,345
New +$148K ﹤0.01% 3646

Other funds holding EFTR

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Raymond James & Associates's EFTR Position: Q2 2024 in Review

Raymond James & Associates sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q2 2024, closing a stake of 12,345 shares — an estimated $178K sold.

Raymond James & Associates first reported a position in EFTR in Q1 2024 and held it in 1 quarter. The position peaked at $178K in Q1 2024. 18 funds tracked by Wall St. Rank hold EFTR as of Q2 2024.

  • Raymond James & Associates reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Raymond James & Associates sold 12,345 eFFECTOR Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $178K.
  • Raymond James & Associates first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q1 2024 and held it in 1 quarter.
  • Raymond James & Associates's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $178K in Q1 2024.
  • 18 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Raymond James & Associates's 13F filing for Q2 2024, filed 19 Jul 2024.